FDA Approves Axsome's Symbravo for Acute Migraine Treatment, Overcoming 2022 Rejection on February 02, 2025 acute Approved meloxicam Migraine Disorders MoSEIC rizatriptan Symbravo Technology United States Food and Drug Administration +